Literature DB >> 4003595

Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels.

D S Janowsky, S C Risch, L Y Huey, B Kennedy, M Ziegler.   

Abstract

In this study, the infusion of physostigmine in 14 patients with affective disorder who were pretreated with methscopolamine caused significant and often profound increases in the patients' epinephrine levels, pulse rates, and blood pressure. Since physostigmine is being used experimentally in the treatment of elderly subjects who have Alzheimer's disease, these cardiovascular effects may have clinical importance.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4003595     DOI: 10.1176/ajp.142.6.738

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  7 in total

1.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

Authors:  Maura L Furey; Wayne C Drevets
Journal:  Arch Gen Psychiatry       Date:  2006-10

2.  Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release.

Authors:  D S Janowsky; S C Risch; B Kennedy; M Ziegler; L Huey
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Cholinergic neurotransmission seems not to be involved in depression but possibly in personality.

Authors:  J Fritze; M Lanczik; E Sofic; M Struck; P Riederer
Journal:  J Psychiatry Neurosci       Date:  1995-01       Impact factor: 6.186

4.  Effect of stress on choline acetyltransferase activity of the brain and the adrenal of the rat.

Authors:  Z Z Wahba; K F Soliman
Journal:  Experientia       Date:  1992-03-15

Review 5.  Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Authors:  Wayne C Drevets; Carlos A Zarate; Maura L Furey
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

Review 6.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression.

Authors:  Wayne C Drevets; Joseph L Price; Maura L Furey
Journal:  Brain Struct Funct       Date:  2008-08-13       Impact factor: 3.270

7.  Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.

Authors:  Lawrence Park; Maura Furey; Allison C Nugent; Cristan Farmer; Jessica Ellis; Joanna Szczepanik; Marc S Lener; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2019-01-01       Impact factor: 5.176

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.